RxDoctor Payments Data

Michael Putman, MD

Rheumatology · Milwaukee, WINPI 1235577016

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,431 of the $13,253 with a category attached, or 86.3%. Novartis accounts for 74.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $6,672, more than ten times the $53 reported in 2019.

$13,253in general payments, 2019–2025

Across 12 payments — averaging $1104.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$10K
  • GSK$2K
  • Fresenius Kabi USA, LLC$1K
  • Amgen$167
  • Johnson & Johnson$53
$158,358in research payments, 2019–2025

Across 10 payments — averaging $15,836 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$66K
  • Amgen$36K
  • AbbVie$31K
  • Novartis$24K

What the payments were for

  • Consulting fees$11,43186%
  • Speaking & faculty fees$1,30010%
  • Food & beverage$4684%
  • Education$530%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$9,911
GSK3$1,821
Fresenius Kabi USA, LLC1$1,300
Amgen3$167
Johnson & Johnson1$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,253 in reported general payments places this provider in the 85th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$27,059
Medicare patients
100
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab31$279,558
Actemra ActpenTocilizumab43$207,317
TavneosAvacopan12$185,519
Enbrel SureclickEtanercept14$101,874
Cimzia (2 Pack)Certolizumab Pegol16$87,798
Humira(Cf)Adalimumab12$73,767
Mycophenolic AcidMycophenolate Sodium17$9,510
Mycophenolate Mofetil20$4,094
Prednisone215$2,092
Azathioprine13$1,203
Hydroxychloroquine Sulfate42$1,081
MethotrexateMethotrexate Sodium41$1,055
Colchicine13$625
Leflunomide13$591
Gabapentin12$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTavneos$167$185,51912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 rheumatology providers in Wisconsin.

Other rheumatology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →